NOD2 and non-small cell lung carcinoma: The experiment showed that the full structure of PTX is necessary to maintain antagonistic activity via MDP activating NOD2 signaling, which results in sensitization of a response to chemotherapy in treating non-small-cell lung cancer (NSCLC).Compounds labelled 24 to 28 are devoid of paclitaxel structure which resulted in significantly lower inhibitory percentages than compound DY-16-43 and nr 23.HEK-Blue hNOD2 cells; Lewis lung carcinoma (LLC) tumor-bearing mice.